Shares of CureVac (NASDAQ:CVAC) have been given an average rating of “Hold” by the six analysts that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $86.50.
CVAC has been the subject of several research analyst reports. Evercore ISI restated a “buy” rating on shares of CureVac in a report on Monday, July 5th. Zacks Investment Research upgraded shares of CureVac from a “sell” rating to a “hold” rating in a research report on Friday, July 16th. Berenberg Bank set a $123.00 price objective on shares of CureVac and gave the company a “buy” rating in a research report on Thursday, July 1st. Finally, Bank of America cut shares of CureVac from a “buy” rating to a “neutral” rating and set a $50.00 price objective for the company. in a research note on Thursday, June 17th.
Several institutional investors have recently bought and sold shares of CVAC. Victory Capital Management Inc. bought a new stake in shares of CureVac in the 1st quarter worth about $2,258,000. Advisors Asset Management Inc. bought a new stake in shares of CureVac in the 1st quarter worth about $83,000. Sector Gamma AS bought a new stake in shares of CureVac in the 1st quarter worth about $2,287,000. Fosun International Ltd bought a new stake in shares of CureVac in the 1st quarter worth about $4,438,000. Finally, Bellevue Group AG boosted its stake in shares of CureVac by 70.0% during the 1st quarter. Bellevue Group AG now owns 28,900 shares of the company’s stock worth $2,643,000 after purchasing an additional 11,900 shares during the period. Hedge funds and other institutional investors own 7.21% of the company’s stock.
CureVac Company Profile
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidate against COVID-19; CV7202, a prophylactic mRNA-based vaccine, which is in Phase 1 clinical trial for rabies virus glycoprotein; vaccine for lassa yellow fever; vaccine for respirational syncytial virus; CV7301, a second-generation lipid nanoparticle flu vaccine; and vaccines for rota, malaria, and universal influenza.
Recommended Story: Dead Cat Bounce
Receive News & Ratings for CureVac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CureVac and related companies with MarketBeat.com's FREE daily email newsletter.